SCHEMBL4052124

SCHEMBL4052124

O=CNc1[c]ccc(N2CCCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
ALDH1A1 P00352 9/20 0.39
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KMT2A Q03164 5/20 0.35
MAPT P10636 5/20 0.35
MEN1 O00255 4/20 0.35
HSD17B10 Q99714 3/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
GAA P10253 2/20 0.35
ALOX15 P16050 2/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 4/20 0.34
TDP1 Q9NUW8 2/20 0.34
TERT O14746 2/20 0.34
HSP90AA1 P07900 1/20 0.34
CCR6 P51684 1/20 0.34
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295987 0.73 MAPT (0.48) ALDH1A1KDM4ESMN1; SMN2KMT2AMAPT
SCHEMBL27778639 0.71 TRIM24 (0.43) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL17805419 0.70 ALDH1A1 (0.50) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL11263589 0.70 ALDH1A1 (0.41) ALDH1A1LMNA
SCHEMBL3140104 0.70 TERT (0.41) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL22484602 0.69 ALDH1A1 (0.49) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL10133331 0.68 TRIM24 (0.57) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL3143049 0.68 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2KMT2AMAPT
SCHEMBL21681490 0.68 TERT (0.40) TRIM24TRIM33ALDH1A1KDM4EKMT2A
SCHEMBL3821638 0.68 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318410-A1 IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS NOVARTIS AG 2009-12-24 US claimed
EP-2079744-A1 IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS Novartis AG (CH) 2009-07-22 EP claimed
EP-1972631-A1 Imidazopyridazines as PI3K lipid kinase inhibitors Novartis AG (CH) 2008-09-24 EP claimed
WO-2008052733-A1 IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-05-08 WO claimed
US-20090318410-A1 IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS NOVARTIS AG 2009-12-24 US disclosed
EP-2079744-A1 IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS Novartis AG (CH) 2009-07-22 EP disclosed
EP-1972631-A1 Imidazopyridazines as PI3K lipid kinase inhibitors Novartis AG (CH) 2008-09-24 EP disclosed
WO-2008052733-A1 IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318410-A1 IMIDAZOPYRIDAZINES AS LIPID KINASE INHIBITORS PI4KA, PIK3CA, PIK3CB TRIM24 2322/4885TRIM33 1873/4885ALDH1A1 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.